Dyadic International, Inc. Stock

$1.00

0.39% yesterday

Nasdaq, Jun 27, 10:00 pm CET

ISIN

US26745T1016

Symbol

DYAI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Dyadic International, Inc. Stock price

$1.00

-7.82 88.67% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

+0.00 0.39%

ISIN

US26745T1016

Symbol

DYAI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$30.1m

Enterprise Value

$27.7m

Net debt

$-2.4m

Cash

$7.4m

Shares outstanding

30.1m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

8.47 | 7.02

EV/Sales

7.80 | 6.47

EV/FCF

negative

P/B

32.54

Financial Health

Equity Ratio

24.88%

Return on Equity

-235.16%

ROCE

-97.02%

ROIC

Debt/Equity

5.42

Financials (TTM | estimate)

Revenue

$3.6m | $4.3m

EBITDA

- | -

EBIT

$-5.8m

Net Income

$-5.8m | $-5.8m

Free Cash Flow

$-4.8m

Growth (TTM | estimate)

Revenue

57.08% | 22.40%

EBITDA

- | -

EBIT

30.51%

Net Income

25.64% | -0.52%

Free Cash Flow

14.87%

Margin (TTM | estimate)

Gross

62.06%

EBITDA

- | -

EBIT

-161.86%

Net

-163.94% | -136.21%

Free Cash Flow

-135.37%

EPS

$-0.20

FCF per Share

$-0.16

Short interest

0.68%

Employees

6.00

Rev per Employee

$580.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Dyadic International, Inc. Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Dyadic International, Inc. forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Dyadic International, Inc. forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from Dyadic International, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	3.55 3.55	57% 57% 100%
- Direct Costs	1.35 1.35	3% 3% 38%
Gross Profit	2.21 2.21	157% 157% 62%
- Selling and Administrative Expenses	5.94 5.94	3% 3% 167%
- Research and Development Expense	2.02 2.02	33% 33% 57%
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-5.75 -5.75	31% 31% -162%
Net Profit	-5.83 -5.83	26% 26% -164%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Dyadic International, Inc. Stock News

Neutral

GlobeNewsWire

●

26 days ago

Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications

Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth markets Leadership team realigned in order to enable execution of ancillary protein strategy Dyadic is well positioned to seize on geopolitical tailwinds driving reshoring/friendshoring of biomanufacturing supply chains to the United States and allies abroad JUPITER, Fla., June 02, 2025 (GLO...

Neutral

GlobeNewsWire

●

about 2 months ago

Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that ...

Neutral

GlobeNewsWire

●

2 months ago

Dyadic to Present at World Vaccine Congress | Washington

JUPITER, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company that utilizes its microbial production platforms to develop commercial cell lines for the efficient large-scale manufacture of proteins for use in human and animal reagents, vaccines and therapeutics, as well as non-pharmaceutical a...

More Dyadic International, Inc. News

Company Profile

Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development, and manufacture of biologic medicines and vaccines. The company was founded by Mark A. Emalfarb in 1979 and is headquartered in Jupiter, FL.

Head office	United States
CEO	Mark Emalfarb
Employees	6
Founded	1979
Website	dyadic.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now